# JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

> **NCT06892431** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Cancer
- Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome
- **DRUG:** JMT101 injection
- **DRUG:** Capecitabine
- **DRUG:** Docetaxel injection
- **DRUG:** Gemcitabine hydrochloride for injection

## Key facts

- **NCT ID:** NCT06892431
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892431, "JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06892431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*